From pneumonia to influenza
-
Upload
society-for-heart-attack-prevention-and-eradication -
Category
Health & Medicine
-
view
13 -
download
0
Transcript of From pneumonia to influenza
D-Stereoisomers of Apo A-I Mimetic Peptides
Given Orally
Reduce Atherosclerosis in Mice
Mohamad Navab
UCLA Cardiology
Objective:
Identification of a class of peptides that are orally administrable and that ameliorate one or more symptoms of atherosclerosis.
Introduction:We have reported that when LDL was incubated with apoA-I or apo A-I peptide mimetics, LDL became resistant to oxidation by artery wall cells in coculture.
Similarly, when the artery wall cells in culture were pretreated with apoA-I, or the peptide mimetics, the cells were no longer capable of oxidizing LDL.
Peripheral human monocytes pre-incubated with apoA-I became similarly incapable of oxidizing LDL.
We showed that apoA-I removed, from LDL, the “seeding molecules” HPETEs and HPODEs that are required for LDL lipid oxidation.
ApoA-I and other exchangeable apolipoproteins, possess lipid-associating domains.
Brouillette & Anantharamaiah (1995), Segrest et al. (1974) Apo A-I has been postulated to possess eight tandem repeating 22mer sequences, most of which have the potential to form class A amphipathic helical structures.
(Segrest et al. 1974)
Apo A-I strongly associates with phospholipids to form complexes and to promote cholesterol efflux from cholesterol-enriched cells.
The delivery and maintenance of serum levels of apo A-I to effectively mitigate one or more symptoms of atherosclerosis has heretofore proven elusive.
Peptides comprising a class A amphipathic helix when formulated with "D" amino acid residue(s) and/or having protected amino and carboxyl termini can be: - orally administered to an organism, - are taken up and delivered to serum
- are effective to mitigate symptoms of atherosclerosis.
Novel peptide administration of which mitigate one or more symptoms of atherosclerosis.
The peptide ranges in length from about 10 to about 30 amino acids, at least one class A amphipathic helix,at least one "D" amino acid residue, protects a phospholipid against oxidation by an oxidizing agent,
Protecting groups include, acetyl, and amide groups coupled to the amino terminus and the carboxyl terminus.
Particularly preferred peptides comprise greater than about 50% amino acid sequence identity with human or mouse apo A-1 or with the polypeptide encoded by the exon encoding a class A amphipathic helix of human or mouse apo A-1.
Peptides formulated using D amino acids, the peptides show dramatically elevated serum half-lives and, particularly when the amino and/or carboxy termini are blocked, can be orally administered.
Such D-form peptides retain the biological activity of the corresponding L-form peptide. In vivo animal studies using such D-form peptides showed effective oral delivery, elevated serum half-life, and the ability to mitigate or prevent/inhibit symptoms of atherosclerosis.
Normal HDL inhibits three steps in the formation of mildly oxidized LDL.
In those studies treating human LDL in vitro with apo A-I or an apo A-I mimetic peptide removed seeding molecules from the LDL that included HPODE and HPETE. These “seeding” molecules were required for cocultures of human artery wall cells to be able to oxidize LDL and for the LDL to induce the artery wall cells to produce monocyte chemotactic activity. We also demonstrated that after injection of apo A-I into mice or infusion into humans, the LDL isolated from the mice or human volunteers after injection/infusion of apo A-I was resistant to oxidation by human artery wall cells and did not induce monocyte chemotactic activity in the artery wall cell cocultures.
It is noted that the fourth exon of apo A-I, when folded into 3.667 residues/turn produces a class A amphipathic helical structure.
One particularly preferred class A peptide, designated 18A (Anantharamaiah, 1986) was modified to produce peptides orally administrable and highly effective at inhibiting or preventing one or more symptoms of atherosclerosis.
The peptides may act in vivo by picking up “seeding molecule(s)” that mitigate oxidation of LDL.
Anantharamaiah’s group determined that increasing the number of Phe residues on the hydrophobic face of the 18A would theoretically increase lipid affinity as determined by computation. Palgunachari et al. (1996)
Apo A-I Peptide Mimetic 2F Hydrophobic face
Hydrophilic faceAmino group
Therefore, initially 5 additional Phe was chosen and hence the peptides designation as 5F.
The 5F peptide was blocked in that the amino terminal residue was acetylated and the carboxyl terminal residue was amidated.
The new class A peptide analog, 5F inhibited , lesion development in atherosclerosis-susceptible mice.
Garber et al. 2000
The peptides used are chemically synthesized using standard chemical peptide synthesis techniques.
Peptides with an additional 2, 3 and 4 Phe would have higher theoretical lipid affinity.
Theoretically, a systematic substitution of residues in the nonpolar face of 18A with Phe could yield six peptides.
ApoA-1 mimetic peptides.
18A D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F
2F Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH2
3F Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-L-K-E-A-F-NH2
3F14 Ac-D-W-L-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2
4F Ac-D-W-F-K-A-F-Y-E-K-V-A-E-K-L-K-E-F-F-NH2
5F Ac-D-W-F-K-A-F-Y-D-K-V-A-E-K-F-K-E-A-F-NH2
6F Ac-D-W-L-K-A-F-Y-D-K-F- F-E-K-F-K-E-F-F-NH2
7F Ac-D-W-F-K-A-F-Y-D-K-F-F- E-K-F-K-E-F-F-NH2
ApoA-I mimetic D-peptides prevent LDL induced monocyte chemotactic activity
Mig
rate
d m
onoc
ytes
per
HPF
D-2F L-2F D-37pA L-37pA
Assay controls
h HDL +
h LD
L
h LDL LDL, NO CELLS
CELLS, N0 LDL µg25
0
125 62 31
+ h LDL
250
125 62 31
0
1
2
3
4
5
6
7
8
9
10
250
125 62 31 250
125 62 31
Increased HDL protective capacity after oral peptide, D-4F in LDL R-/- mice
0
1
2
3
4
5
6
7
8
9
m HDL + LDL
Saline D - 4 FL- 4 F
Mig
rate
d m
onoc
ytes
per
HPF
100 µg50
P<.01
100 µg50 100 µg50
No Addition
h LDL
h LDL +h HDL HDL
Assay Controls
0
1
2
3
4
5
6
7
8
9
Saline L- 4F D - 4F
m VLDL+ m LDL
Mig
rate
d m
onoc
ytes
per
HPF
No Addition
h LDL
h LDL + h HDL
Assay Controls
m LDL
Saline L- 4F D-4F
P<.001
P<.001
Increased resistance to oxidation for LDL after oral peptide, D - 4F in LDL R-/- mice
FPLC Fraction Number
02468
6050403020100
605040302010002468
L-4F
D-4F 24 hr .
5 min. 45 min.
60504030201000
2 4
6
8
60504030201000
2
4
6
8L-4F
D-4F
6050403020100
D-4F
6050403020100
0
2
4
6
8
02468
L-4F
3 hr.
FPLC Fraction Number
60504030201000
2
4
68
60504030201000
24
6
8
D-4F
L-4F
Cho
lest
erol
, m
g/dl
0
10
20 LDL HDL
125 I
, CPM
x 1
0-3
5040302010
125 I
, CPM
x 1
0-3
Plasma radioactivity following oral administration of 125I- 4F peptide
cpm
/ml p
lasm
a
0
2,000
4,000
6,000
8,000
10,000
12,000
Intact18 mer
Free counts L - 4F
6040200 10 30 50
D - 4F
0
cpm
/ml p
lasm
a2,000
4,000
6,000
8,000
10,000
12,000
6040200 10 30 50
Intact D-4F in plasma at 4 hrs
HPLC Fractions
High levels of radioactivity in mouse urine following oral administration of 125 I - L- 4F
cpm
/ 50
µl u
rine
30 60 120 240 min
0
2 000 000
4 000 000
6 000 000
8 000 000
Time after gavage with 125 I-4F
L - 4FD - 4F
20
30
40
50
60
70
80
90
100
110
120
130
Aort
ic r
oot
lesi
on a
rea
µm 2
x 1
0 -3 p
er s
ecti
on
D - 5 FSaline
84,495
50,100
41%
Reduction by D-5F of lesion scores in LDL receptor deficient mice on a Western type diet.
P<0.026
0
10
20
30
40
50
60
P< .01
81 %
Saline D- 4F
Aort
ic r
oot
lesi
on a
rea
µm 2
x 1
0 -3 p
er s
ecti
on
-
0
5
5
0
0
5
1
1
20
2
3
3 5
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Cho
lest
erol
(mg/
dl)
FPLC Fractions
ControlD-4F
Plasma cholesterol in LDL R-/- mice gavaged with D-4F for 6 weeks
In Progress
0
5
10
15
20
25
30
35
40
13 1415 1617 18 1920 2122 23 2425 26 2728 2930 31 3233 3435 36
Chol
este
rol
(mg/
dl)
ControlD-4F
Plasma cholesterol in apoE null mice on D-4F in drinking water for 5 weeks
FPLC Fractions
PON activity in apoE null mice on D-4F in drinking water for 5 weeksPa
raox
onas
e Ac
tivi
ty ,
unit
s/m
l pla
sma
0
10
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Control+ D-4F
2
4
6
8
FPLC Fractions
Peptides formulated using D amino acids show dramatically elevated serum half-lives and, particularly when the amino and/or carboxy termini are blocked, can be orally administered.
Such D-form peptides retain the biological activity of the corresponding L-form peptide. In vivo animal studies using such D-form peptides showed effective oral delivery, elevated serum half-life, and the ability to markedly reduce atherosclerotic lesions.
Conclusion